Other Causes. Genus may terminate this Agreement immediately upon written notice to Poseida if Poseida (or an Affiliate or Sublicensee) fails to initiate a Phase I clinical trial for a Licensed Product within twenty (20) months after receiving approval of an IND filed by Poseida (or such Affiliate or Sublicensee) with respect to such Licensed Product.
Appears in 2 contracts
Sources: License Agreement (Poseida Therapeutics, Inc.), License Agreement (Poseida Therapeutics, Inc.)